<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02217137</url>
  </required_header>
  <id_info>
    <org_study_id>R1108/10/2014</org_study_id>
    <secondary_id>2014/269/A</secondary_id>
    <nct_id>NCT02217137</nct_id>
  </id_info>
  <brief_title>Tear Proteins, Conjunctival Cells and Imaging Eyes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients</brief_title>
  <official_title>Analysing Tear Protein, Conjunctival Cells, and Imaging Eyes in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore National Eye Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore National Eye Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic systemic&#xD;
      autoimmune diseases that have been reported to affect the ocular surface of patients [1,2].&#xD;
      However, the nature of the disturbances of the ocular surface immunity and their relationship&#xD;
      to systemic disease severity are poorly understood.&#xD;
&#xD;
      This study aims to profile the ocular surface inflammation of RA and SLE patients by a.,&#xD;
      analysing levels of tear cytokine, and b., investigating conjunctival cells, and c. clinical&#xD;
      imaging for conjunctival redness and tear stability.&#xD;
&#xD;
      20 consecutive RA patients and 20 consecutive SLE patients will be recruited from the&#xD;
      Singapore General Hospital Rheumatology clinic. 20 age matched controls for SLE and another&#xD;
      20 age matched controls for RA will be recruited.&#xD;
&#xD;
      All participants will undergo&#xD;
&#xD;
        1. Tear collection with Schirmer strips&#xD;
&#xD;
        2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling&#xD;
&#xD;
        3. Clinical ocular surface assessment with Oculus Keratograph 5M&#xD;
&#xD;
        4. Collection of blood via venipuncture (optional)&#xD;
&#xD;
        5. Retrieval of Clinical Information of participants&#xD;
&#xD;
      The association of cytokines in the tears with various cellular and immune markers, as well&#xD;
      as clinical signs of inflammation and tear stability will be investigated. This will be&#xD;
      useful for further longitudinal studies of treatment in autoimmmune disease patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Rationale&#xD;
&#xD;
      Inflammatory autoimmune disease and eye involvement Rheumatoid Arthritis (RA) and Systemic&#xD;
      Lupus Erythematosus (SLE) are chronic systemic autoimmune diseases of unknown etiology [2].&#xD;
      Ocular manifestations may range from conditions which cause distressing symptoms of&#xD;
      discomfort, such as dry eye syndrome, to potentially sight-threatening conditions such as&#xD;
      retinal vasculitis. The ocular surface is agreed to be the site most commonly affected by&#xD;
      systemic autoimmune diseases, manifesting as dry eye syndrome. However, its related&#xD;
      complications are poorly addressed [1,2]. The severity of ocular surface inflammation may be&#xD;
      related to systemic immunology since systemic treatment will alter the signs of ocular&#xD;
      surface disease.&#xD;
&#xD;
      EyePRIMTM (Opia Technologies) Impression Cytology Device Studies have shown that this method&#xD;
      of combining flow cytometry with OSIC is useful to phenotype recovered cells from the&#xD;
      superficial layers of the ocular surface [3]. There has been recent advances in clinical&#xD;
      techniques for obtaining conjunctival cells for reseach studies. An example of an award&#xD;
      winning device is the EyePRIMTM (Opia Technologies).&#xD;
&#xD;
      Previous studies have shown that EyePRIMTM is able to obtain sufficient cells for flow&#xD;
      cytometry for immune markers [4]. In the study, the ocular surface of three healthy patients&#xD;
      were analysed using EyePRIMTM and conventional semi-circular Supor PES filters for flow&#xD;
      cytometry. One EyePRIMTM was used to impression the lateral bulbar conjunctiva and a second,&#xD;
      the medial bulbar conjunctiva of the same eye. Cells were recovered from both EyePRIMTM using&#xD;
      gentle agitation with a pipette tip for one minute, and then stained with antibody markers&#xD;
      for leukocytes (CD45), CD16, epCAM, HLA-DR and a dead cell exclusion dye. Results have shown&#xD;
      that the mean corrected total cell count collected using EyePRIMTM was greater than&#xD;
      conventional methods (475,544 cells vs 335,226 cells). Out of the total cells collected, the&#xD;
      mean corrected number of lymphocytes found via staining with CD45 antibody was around 1000.&#xD;
&#xD;
      Advances in clinical phenotyping Dry eye is a common ocular surface disease mediated by&#xD;
      inflammation. It is postulated that dry eye in the context of systemic autoimmune diseases is&#xD;
      caused by the infiltration of activated T lymphocytes into the bulbar conjunctiva, beginning&#xD;
      a vicious cycle of chronic inflammation of the ocular surface [5]. In the dry eye database at&#xD;
      SNEC/SERI (unpublished data), we found higher levels of fluorescein corneal staining,&#xD;
      indicating presence of punctate epithelial erosions in patients with RA compared to dry eye&#xD;
      patients without systemic autoimmune diseases. While we have not personally conducted studies&#xD;
      on SLE patients, it is documented in existing literature that significant signs of dry eye&#xD;
      have been detected in SLE patients using older assessment modalities such as the Schirmer's&#xD;
      test and Rose Bengal staining [6].&#xD;
&#xD;
      Lastly, the availability of new phenotyping equipment such as the Oculus Keratograph 5M&#xD;
      provides the opportunity for clinical parameters such as conjunctival redness and&#xD;
      non-invasive tear break up time (NIBUT) to be assessed objectively, accurately and&#xD;
      non-invasively [7]. To the best of the investigators' knowledge, these standardised tools&#xD;
      have not been used in the context of rheumatological disease or its effect on the ocular&#xD;
      surface.&#xD;
&#xD;
      Research experience at SERI In SERI there is significant experience with clinical and imaging&#xD;
      studies of the ocular surface. The clinical profile of the ocular surface inflammation can be&#xD;
      objectively measured or documented using newly available imaging techniques as described. In&#xD;
      addition, a TCR grant will be jointly applied for in the coming months to examine systemic as&#xD;
      well as ocular immune events during treatment of rheumatology patients including RA and SLE.&#xD;
&#xD;
      Preliminary data Our research team has experience with extraction of tear proteins from&#xD;
      schirmer strips in a longitudinal trial and analysing after each patient's visit, tear&#xD;
      cytokine concentrations for IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFN , TNFa , IL-12, IL-13,&#xD;
      IL-17a, MCP, MIP1a, MMP9, IP10, RANTES using the BioPlex technique (Figure 1).&#xD;
&#xD;
      In other studies (unpublished data), our research group has successfully performed flow&#xD;
      cytometry, and evaluated the proportion of various immune cell types by staining for cell&#xD;
      surface markers. This study was performed on pterygium tissues. We were able to perform&#xD;
      intracytoplasmic staining for cytokines after Phorbol Myristate Acetate (PMA) stimulation.&#xD;
      This was performed for Th1 (eg. TNFα and IFN γ) and Th17 (eg. IL-17a) cytokines, from&#xD;
      populations of T lymphocytes as few as 300-500.&#xD;
&#xD;
      1. HYPOTHESIS AND OBJECTIVES&#xD;
&#xD;
      Hypothesis and specific aims This study thus aims to profile the ocular surface inflammation&#xD;
      of RA and SLE patients by a., analysing levels of tear cytokine, and b., investigating&#xD;
      conjunctival cells, and c. clinical imaging for conjunctival redness and tear stability. In&#xD;
      the conjunctiva of the patients, we expect to find conjunctival epithelial cells, stromal&#xD;
      fibroblasts as well as various immune cells.&#xD;
&#xD;
      Study Objectives and Purpose&#xD;
&#xD;
        1. A primary purpose of the study is to profile A. tear cytokine levels and B. the&#xD;
           proportion of various immune cells (eg., lymphocyte, dendritic cell and neutrophil&#xD;
           subsets) in the conjunctival impressions.&#xD;
&#xD;
        2. The secondary aim is to further profile the immune response, either by examining the&#xD;
           possible Th1 and Th17 responses of T cells to stimulation, or by the levels of&#xD;
           inflammatory gene transcripts, ie., pattern of immune gene expression.&#xD;
&#xD;
        3. A third aim is to study the correlation between the activity of systemic disease, ocular&#xD;
           surface status, and tear cytokine and immune cell levels of RA and SLE patients.&#xD;
&#xD;
      Outcomes 1. Tear cytokine levels 2. Conjunctival immune cell profile&#xD;
&#xD;
        1. Proportion of T lymphocytes and other immune cells&#xD;
&#xD;
        2. Immune gene expression 3. Clinical parameters for ocular surface: Conjunctival redness,&#xD;
           tear meniscus height and NIBUT 4. Rheumatological disease activity indices of the&#xD;
           patients&#xD;
&#xD;
           Primary outcome:&#xD;
&#xD;
           Tear cytokine levels and conjunctival immune cell profile of RA and SLE patients in&#xD;
           comparison to healthy controls&#xD;
&#xD;
           2. EXPECTED RIKS AND BENEFITS Expected risks No potential problems are expected for this&#xD;
           study.&#xD;
&#xD;
           Potential benefits With greater understanding of the presence of various inflammatory&#xD;
           mediators, we can gain further insight into the complex process taking place. It is also&#xD;
           possible that some markers like tear proteins can be biomarkers that warn individuals of&#xD;
           systemic flares. We have jointly filed a provisional patent on such tear biomarkers in&#xD;
           SLE flares. (Date of Filing: 11 September 2013 Singapore Provisional Patent Application&#xD;
           No.: 201306892-9).&#xD;
&#xD;
           3. STUDY POPULATION 3.1. List the number and nature of subjects to be enrolled.&#xD;
           Participants and target sample size 20 consecutive RA patients and 20 consecutive SLE&#xD;
           patients, aged 21 to 99, will be recruited from the Singapore General Hospital, under&#xD;
           three settings a., SGH Rheumatology outpatients b., Rheumatology patients from the&#xD;
           wards, c., Patients from pilot project under Dr Tan (CIRB REF: 2013/152/E).&#xD;
&#xD;
           Permission would be sought from the attending doctors before subjects are being&#xD;
           recruited. Eligible subjects will be counselled on the study by the study coordinator.&#xD;
           If the subject is interested, the study coordinator will then accompany the subject to&#xD;
           SERI for the relevant assessments. Informed written consent will be obtained from all&#xD;
           participants.&#xD;
&#xD;
           In addition, we will recruit 20 age matched controls for SLE and similarly another 20&#xD;
           controls for RA. If older controls are required, they will be from the pre-cataract&#xD;
           patients, and younger ones from volunteers and other students. They will undergo the&#xD;
           same assessments as the patients in the other groups. Publicity for the study will be&#xD;
           carried out via posters or word of mouth (draft of poster is submitted for approval).&#xD;
&#xD;
           3.2. Inclusion Criteria&#xD;
&#xD;
           1. Clinically diagnosed with Rheumatoid Arthritis or Systemic Lupus Erythematosus.&#xD;
&#xD;
           3.3. Exclusion Criteria&#xD;
&#xD;
           All subjects meeting any of the exclusion criteria at baseline will be excluded from&#xD;
           participation.&#xD;
&#xD;
           1. Known history of thyroid disorders (diagnosed by physician). 2. No ocular surgery&#xD;
           within the last 3 months and LASIK within 1 year. 3. Ocular surface diseases such as&#xD;
           pterygium, or obvious lid/orbital disease with lagophthalmos.&#xD;
&#xD;
           4. Any other specified reason as determined by clinical investigator.&#xD;
&#xD;
           4. STUDY DESIGN AND PROCEDURES/METHODOLOGY&#xD;
&#xD;
           Study Design:&#xD;
&#xD;
           Prospective study&#xD;
&#xD;
           No. of visits:&#xD;
&#xD;
           There will only be 1 study visit in this study.&#xD;
&#xD;
           Duration of Study:&#xD;
&#xD;
           11 months (Apr 2014 to Mar 2015). Recruitment of patients and collection of data will&#xD;
           take place from 22nd May 2014 to 31 July 2014.&#xD;
&#xD;
           Procedures:&#xD;
&#xD;
           The different procedures proposed in this small study are summarized below, and&#xD;
           elaborated upon in subsequent paragraphs:&#xD;
&#xD;
             1. Tear collection with Schirmer strips&#xD;
&#xD;
             2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling&#xD;
&#xD;
             3. Clinical ocular surface assessment with Oculus Keratograph 5M&#xD;
&#xD;
             4. Collection of blood via venipuncture (optional)&#xD;
&#xD;
             5. Retrieval of Clinical Information of participants&#xD;
&#xD;
             1. a. Schirmer's I test This will be done with the standard strips currently used at&#xD;
                SERI (5 mm wide with a notch for folding) (Schirmer Tear Test Strips, Clement&#xD;
                Clarke International, UK). No prior anaesthetic will be used. The strips will be&#xD;
                positioned over the temporal half of the lower lid margin in both eyes at the same&#xD;
                time.&#xD;
&#xD;
           The study participant will be asked to close their eyes. Any excessive irritation signs&#xD;
           will be noted. The extent of the wetting in each strip will be recorded after 5 minutes&#xD;
           of testing. The strip will be collected and stored in 1.5ml Eppendorf tubes at -80˚C&#xD;
           until further cytokine analysis.&#xD;
&#xD;
           1b. Tear cytokine level measurement with BioPlex Human Cytokine Assay We propose&#xD;
           analyzing tear cytokine levels from tears collected on Schirmer strips. In previous&#xD;
           studies on dry eye patients being treated with punctal occlusion, we were able to elute&#xD;
           proteins from Schirmer strips and determine levels of 15 cytokines. Tear proteins will&#xD;
           be extracted as in previous protocols at SERI [8]. Briefly, we will cut out the wetted&#xD;
           portions of the strips and vortex after adding phosphate buffered saline in protease&#xD;
           inhibitor.&#xD;
&#xD;
           The assay will be using a commercially available bead based indirect sandwich&#xD;
           immunofluorescence assay (Beadlyte Kit). The readout will be performed with the Bioplex&#xD;
           (BIO-RAD) platform. Cytokine standard provided with the kit will be used to plot&#xD;
           standard curves. The levels of cytokines in tears are normalised to per mm of Schirmer&#xD;
           and further analysed. We believe this same method of tear-sample collection will be just&#xD;
           as effective in assessing patients with RA/SLE.&#xD;
&#xD;
           2. Impression cytology Impression cytology will be performed to collect the superficial&#xD;
           conjunctiva cells for analysis. Conjunctiva impression specimen of the upper bulbar&#xD;
           conjunctiva will be collected with the EyePRIMTM device.&#xD;
&#xD;
           One drop of topical anaesthesia (eg. alcaine) is instilled. The eyelid will be held open&#xD;
           with the thumb and forefinger. The distal end of the device will be positioned on the&#xD;
           conjunctiva of the participant. The inner radius can be positioned adjacent to the&#xD;
           limbus. The push-button will be pressed until the membrane is in contact with the&#xD;
           temporal bulbar conjunctiva, holding for 2 to 3 seconds. It will then be removed from&#xD;
           the conjunctiva with a peeling motion after 2-3 seconds. The membrane will subsequently&#xD;
           be placed in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum..&#xD;
           This will be carried out over the temporal bulbar conjunctiva of both eyes. Each&#xD;
           participant will then be given a single-use container of Refresh Plus ® artificial tears&#xD;
           for self-application in case any ocular irritation is felt after impression cytology.&#xD;
&#xD;
           The cells can then be processed after the patient's visit. Cells will be recovered from&#xD;
           the EyePRIMTM filters using gentle agitation with a pipette tip for one minute, and then&#xD;
           stained with antibody markers for dendritic cells (lymphoid and myeloid), NK cells, B&#xD;
           cells, T cells , neutrophils and monocytes. Specifically, CD123, CD16, CD45, CD56, CD3,&#xD;
           CD4, CD8, CD66b, CD11b, CD11c markers will be used.&#xD;
&#xD;
           Cells harvested from impression cytology will be counted and undergo flow cytometry and&#xD;
           depending on numbers, determination of the proportion of immune cells of various types,&#xD;
           and even staining for Intracytoplasmic cytokines in lymphocytes after Phorbol Myristate&#xD;
           Acetate stimulation. One modification of flow cytometry is the Amnis or microscopy&#xD;
           coupled flow cytometry which can be performed at the SingHealth Immunology and&#xD;
           Inflammation center. Amnis and microscopy couples flow cytometry can handle even less&#xD;
           cells than conventional flow cytometry. If the cells from impression cytology are not&#xD;
           sufficient for these purposes, nano-string transcript levels of various immune markers&#xD;
           will be performed instead.&#xD;
&#xD;
           3. Oculus K 5M imaging&#xD;
&#xD;
      a. Non-Invasive Tear Break-Up Time (Oculus K5M) Non-Invasive Tear Break-Up Time is measured&#xD;
      non-invasively and fully automatically using Oculus K5M. The new infrared illumination is not&#xD;
      visible to the human eye. This prevents glare during the examination. Patient will sit&#xD;
      comfortably in front of the instrument and blink freely while fixing on a target directly&#xD;
      ahead. Once the participant is ready, they will be instructed to blink twice and refrain from&#xD;
      blinking. Keratograph 5M is fully automated and it will capture any break or distortion in&#xD;
      the image and the time of the break will be noted. Three readings will be taken for each eye&#xD;
      to get the average value.&#xD;
&#xD;
      b. Tear Meniscus Height (Oculus K5M) This can be measured non-invasively by the Oculus K5M to&#xD;
      the nearest mm. Patient will sit comfortably in front of the instrument while fixing on a&#xD;
      target directly ahead. Tear meniscus will be captured by the machine and tear meniscus height&#xD;
      measured.&#xD;
&#xD;
      c. Conjunctival redness (Oculus K5M) Conjunctival redness will be assessed using Oculus K5M.&#xD;
      Patient will sit comfortably in front of the instrument while fixing on a target directly&#xD;
      ahead. Imaged will be captured and an overview display of conjunctival redness will be&#xD;
      evaluated by &quot;JENVIS Grading Scale&quot;.&#xD;
&#xD;
      4. Collection of blood via venipuncture (optional) 5-10ml of blood will be collected from&#xD;
      patients via venipuncture. This is optional based on participant preference. Two different&#xD;
      Participant Information Sheets have been prepared based on their choice of having&#xD;
      venipuncture and disclosing its results. This will be taken on a non-study visit or when it&#xD;
      is concurrent with a clinically indicated blood test.&#xD;
&#xD;
      5. Retrieval of Clinical Information of participants&#xD;
&#xD;
      Three areas of clinical information of the rheumatic status in our participants will be&#xD;
      collected retrospectively. These areas are:&#xD;
&#xD;
        1. Most recent serology results for autoantibody titres and other blood test results such&#xD;
           as erythrocyte sedimentation rate&#xD;
&#xD;
        2. History of drug prescriptions&#xD;
&#xD;
        3. Disease activity index and other relevant clinical information&#xD;
&#xD;
      We propose obtaining the data in 1) and 2) from the patient's electronic medical records via&#xD;
      the Citrix XenApp portal. Disease activity index and other clinical information may be&#xD;
      obtained from the case files of the patients.&#xD;
&#xD;
      Rationale Small volumes of fluid can be used in a multiplex way to determine more than one&#xD;
      cytokine in the Beadlyte assay, compared to ELISA.&#xD;
&#xD;
      The EyePRIMTM technique is used because of prior studies that showed a high cellular yield&#xD;
      and success in immune profiling with 3 healthy people.&#xD;
&#xD;
      Expected findings:&#xD;
&#xD;
        1. RA and SLE patients should have elevated tear cytokine levels and increased inflammatory&#xD;
           cell population in their conjunctival samples.&#xD;
&#xD;
        2. RA and SLE patients should have greater signs of ocular surface inflammation than the&#xD;
           healthy controls&#xD;
&#xD;
        3. The signs of ocular surface inflammation should correlate with disease activity, tear&#xD;
           cytokines profiles and conjunctival inflammatory cell profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Profile tear cytokines</measure>
    <time_frame>1 day</time_frame>
    <description>the inflammatory cytokines concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile immune response</measure>
    <time_frame>1 day</time_frame>
    <description>the levels of inflammatory gene transcripts, ie., pattern of immune gene expression.</description>
  </secondary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Dry Eye</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tear samples will be collected from the schimers strips for protein analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid Arthriris, Systemic Lupus Erythematosus and healthy normal volunteers will be&#xD;
        recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically diagnosed with Rheumatoid Arthritis or Systemic Lupus Erythematosus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of thyroid disorders (diagnosed by physician).&#xD;
&#xD;
          -  No ocular surgery within the last 3 months and LASIK within 1 year.&#xD;
&#xD;
          -  Ocular surface diseases such as pterygium, or obvious lid/orbital disease with&#xD;
             lagophthalmos.&#xD;
&#xD;
          -  Any other specified reason as determined by clinical investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Singapore Eye Research Institute</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singapore National Eye Centre</investigator_affiliation>
    <investigator_full_name>Louis Tong</investigator_full_name>
    <investigator_title>Clinician-Scientist, Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Tear cytokines and immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02217137
org study id: R1108/10/2014
secondary id: 2014/269/A
nct id: NCT02217137
lead sponsor: 
has dmc: No
Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic systemic
      autoimmune diseases that have been reported to affect the ocular surface of patients [1,2].
      However, the nature of the disturbances of the ocular surface immunity and their relationship
      to systemic disease severity are poorly understood.

      This study aims to profile the ocular surface inflammation of RA and SLE patients by a.,
      analysing levels of tear cytokine, and b., investigating conjunctival cells, and c. clinical
      imaging for conjunctival redness and tear stability.

      20 consecutive RA patients and 20 consecutive SLE patients will be recruited from the
      Singapore General Hospital Rheumatology clinic. 20 age matched controls for SLE and another
      20 age matched controls for RA will be recruited.

      All participants will undergo

        1. Tear collection with Schirmer strips

        2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling

        3. Clinical ocular surface assessment with Oculus Keratograph 5M

        4. Collection of blood via venipuncture (optional)

        5. Retrieval of Clinical Information of participants

      The association of cytokines in the tears with various cellular and immune markers, as well
      as clinical signs of inflammation and tear stability will be investigated. This will be
      useful for further longitudinal studies of treatment in autoimmmune disease patients.
Background and Rationale

      Inflammatory autoimmune disease and eye involvement Rheumatoid Arthritis (RA) and Systemic
      Lupus Erythematosus (SLE) are chronic systemic autoimmune diseases of unknown etiology [2].
      Ocular manifestations may range from conditions which cause distressing symptoms of
      discomfort, such as dry eye syndrome, to potentially sight-threatening conditions such as
      retinal vasculitis. The ocular surface is agreed to be the site most commonly affected by
      systemic autoimmune diseases, manifesting as dry eye syndrome. However, its related
      complications are poorly addressed [1,2]. The severity of ocular surface inflammation may be
      related to systemic immunology since systemic treatment will alter the signs of ocular
      surface disease.

      EyePRIMTM (Opia Technologies) Impression Cytology Device Studies have shown that this method
      of combining flow cytometry with OSIC is useful to phenotype recovered cells from the
      superficial layers of the ocular surface [3]. There has been recent advances in clinical
      techniques for obtaining conjunctival cells for reseach studies. An example of an award
      winning device is the EyePRIMTM (Opia Technologies).

      Previous studies have shown that EyePRIMTM is able to obtain sufficient cells for flow
      cytometry for immune markers [4]. In the study, the ocular surface of three healthy patients
      were analysed using EyePRIMTM and conventional semi-circular Supor PES filters for flow
      cytometry. One EyePRIMTM was used to impression the lateral bulbar conjunctiva and a second,
      the medial bulbar conjunctiva of the same eye. Cells were recovered from both EyePRIMTM using
      gentle agitation with a pipette tip for one minute, and then stained with antibody markers
      for leukocytes (CD45), CD16, epCAM, HLA-DR and a dead cell exclusion dye. Results have shown
      that the mean corrected total cell count collected using EyePRIMTM was greater than
      conventional methods (475,544 cells vs 335,226 cells). Out of the total cells collected, the
      mean corrected number of lymphocytes found via staining with CD45 antibody was around 1000.

      Advances in clinical phenotyping Dry eye is a common ocular surface disease mediated by
      inflammation. It is postulated that dry eye in the context of systemic autoimmune diseases is
      caused by the infiltration of activated T lymphocytes into the bulbar conjunctiva, beginning
      a vicious cycle of chronic inflammation of the ocular surface [5]. In the dry eye database at
      SNEC/SERI (unpublished data), we found higher levels of fluorescein corneal staining,
      indicating presence of punctate epithelial erosions in patients with RA compared to dry eye
      patients without systemic autoimmune diseases. While we have not personally conducted studies
      on SLE patients, it is documented in existing literature that significant signs of dry eye
      have been detected in SLE patients using older assessment modalities such as the Schirmer's
      test and Rose Bengal staining [6].

      Lastly, the availability of new phenotyping equipment such as the Oculus Keratograph 5M
      provides the opportunity for clinical parameters such as conjunctival redness and
      non-invasive tear break up time (NIBUT) to be assessed objectively, accurately and
      non-invasively [7]. To the best of the investigators' knowledge, these standardised tools
      have not been used in the context of rheumatological disease or its effect on the ocular
      surface.

      Research experience at SERI In SERI there is significant experience with clinical and imaging
      studies of the ocular surface. The clinical profile of the ocular surface inflammation can be
      objectively measured or documented using newly available imaging techniques as described. In
      addition, a TCR grant will be jointly applied for in the coming months to examine systemic as
      well as ocular immune events during treatment of rheumatology patients including RA and SLE.

      Preliminary data Our research team has experience with extraction of tear proteins from
      schirmer strips in a longitudinal trial and analysing after each patient's visit, tear
      cytokine concentrations for IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFN , TNFa , IL-12, IL-13,
      IL-17a, MCP, MIP1a, MMP9, IP10, RANTES using the BioPlex technique (Figure 1).

      In other studies (unpublished data), our research group has successfully performed flow
      cytometry, and evaluated the proportion of various immune cell types by staining for cell
      surface markers. This study was performed on pterygium tissues. We were able to perform
      intracytoplasmic staining for cytokines after Phorbol Myristate Acetate (PMA) stimulation.
      This was performed for Th1 (eg. TNFα and IFN γ) and Th17 (eg. IL-17a) cytokines, from
      populations of T lymphocytes as few as 300-500.

      1. HYPOTHESIS AND OBJECTIVES

      Hypothesis and specific aims This study thus aims to profile the ocular surface inflammation
      of RA and SLE patients by a., analysing levels of tear cytokine, and b., investigating
      conjunctival cells, and c. clinical imaging for conjunctival redness and tear stability. In
      the conjunctiva of the patients, we expect to find conjunctival epithelial cells, stromal
      fibroblasts as well as various immune cells.

      Study Objectives and Purpose

        1. A primary purpose of the study is to profile A. tear cytokine levels and B. the
           proportion of various immune cells (eg., lymphocyte, dendritic cell and neutrophil
           subsets) in the conjunctival impressions.

        2. The secondary aim is to further profile the immune response, either by examining the
           possible Th1 and Th17 responses of T cells to stimulation, or by the levels of
           inflammatory gene transcripts, ie., pattern of immune gene expression.

        3. A third aim is to study the correlation between the activity of systemic disease, ocular
           surface status, and tear cytokine and immune cell levels of RA and SLE patients.

      Outcomes 1. Tear cytokine levels 2. Conjunctival immune cell profile

        1. Proportion of T lymphocytes and other immune cells

        2. Immune gene expression 3. Clinical parameters for ocular surface: Conjunctival redness,
           tear meniscus height and NIBUT 4. Rheumatological disease activity indices of the
           patients

           Primary outcome:

           Tear cytokine levels and conjunctival immune cell profile of RA and SLE patients in
           comparison to healthy controls

           2. EXPECTED RIKS AND BENEFITS Expected risks No potential problems are expected for this
           study.

           Potential benefits With greater understanding of the presence of various inflammatory
           mediators, we can gain further insight into the complex process taking place. It is also
           possible that some markers like tear proteins can be biomarkers that warn individuals of
           systemic flares. We have jointly filed a provisional patent on such tear biomarkers in
           SLE flares. (Date of Filing: 11 September 2013 Singapore Provisional Patent Application
           No.: 201306892-9).

           3. STUDY POPULATION 3.1. List the number and nature of subjects to be enrolled.
           Participants and target sample size 20 consecutive RA patients and 20 consecutive SLE
           patients, aged 21 to 99, will be recruited from the Singapore General Hospital, under
           three settings a., SGH Rheumatology outpatients b., Rheumatology patients from the
           wards, c., Patients from pilot project under Dr Tan (CIRB REF: 2013/152/E).

           Permission would be sought from the attending doctors before subjects are being
           recruited. Eligible subjects will be counselled on the study by the study coordinator.
           If the subject is interested, the study coordinator will then accompany the subject to
           SERI for the relevant assessments. Informed written consent will be obtained from all
           participants.

           In addition, we will recruit 20 age matched controls for SLE and similarly another 20
           controls for RA. If older controls are required, they will be from the pre-cataract
           patients, and younger ones from volunteers and other students. They will undergo the
           same assessments as the patients in the other groups. Publicity for the study will be
           carried out via posters or word of mouth (draft of poster is submitted for approval).

           3.2. Inclusion Criteria

           1. Clinically diagnosed with Rheumatoid Arthritis or Systemic Lupus Erythematosus.

           3.3. Exclusion Criteria

           All subjects meeting any of the exclusion criteria at baseline will be excluded from
           participation.

           1. Known history of thyroid disorders (diagnosed by physician). 2. No ocular surgery
           within the last 3 months and LASIK within 1 year. 3. Ocular surface diseases such as
           pterygium, or obvious lid/orbital disease with lagophthalmos.

           4. Any other specified reason as determined by clinical investigator.

           4. STUDY DESIGN AND PROCEDURES/METHODOLOGY

           Study Design:

           Prospective study

           No. of visits:

           There will only be 1 study visit in this study.

           Duration of Study:

           11 months (Apr 2014 to Mar 2015). Recruitment of patients and collection of data will
           take place from 22nd May 2014 to 31 July 2014.

           Procedures:

           The different procedures proposed in this small study are summarized below, and
           elaborated upon in subsequent paragraphs:

             1. Tear collection with Schirmer strips

             2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling

             3. Clinical ocular surface assessment with Oculus Keratograph 5M

             4. Collection of blood via venipuncture (optional)

             5. Retrieval of Clinical Information of participants

             1. a. Schirmer's I test This will be done with the standard strips currently used at
                SERI (5 mm wide with a notch for folding) (Schirmer Tear Test Strips, Clement
                Clarke International, UK). No prior anaesthetic will be used. The strips will be
                positioned over the temporal half of the lower lid margin in both eyes at the same
                time.

           The study participant will be asked to close their eyes. Any excessive irritation signs
           will be noted. The extent of the wetting in each strip will be recorded after 5 minutes
           of testing. The strip will be collected and stored in 1.5ml Eppendorf tubes at -80˚C
           until further cytokine analysis.

           1b. Tear cytokine level measurement with BioPlex Human Cytokine Assay We propose
           analyzing tear cytokine levels from tears collected on Schirmer strips. In previous
           studies on dry eye patients being treated with punctal occlusion, we were able to elute
           proteins from Schirmer strips and determine levels of 15 cytokines. Tear proteins will
           be extracted as in previous protocols at SERI [8]. Briefly, we will cut out the wetted
           portions of the strips and vortex after adding phosphate buffered saline in protease
           inhibitor.

           The assay will be using a commercially available bead based indirect sandwich
           immunofluorescence assay (Beadlyte Kit). The readout will be performed with the Bioplex
           (BIO-RAD) platform. Cytokine standard provided with the kit will be used to plot
           standard curves. The levels of cytokines in tears are normalised to per mm of Schirmer
           and further analysed. We believe this same method of tear-sample collection will be just
           as effective in assessing patients with RA/SLE.

           2. Impression cytology Impression cytology will be performed to collect the superficial
           conjunctiva cells for analysis. Conjunctiva impression specimen of the upper bulbar
           conjunctiva will be collected with the EyePRIMTM device.

           One drop of topical anaesthesia (eg. alcaine) is instilled. The eyelid will be held open
           with the thumb and forefinger. The distal end of the device will be positioned on the
           conjunctiva of the participant. The inner radius can be positioned adjacent to the
           limbus. The push-button will be pressed until the membrane is in contact with the
           temporal bulbar conjunctiva, holding for 2 to 3 seconds. It will then be removed from
           the conjunctiva with a peeling motion after 2-3 seconds. The membrane will subsequently
           be placed in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum..
           This will be carried out over the temporal bulbar conjunctiva of both eyes. Each
           participant will then be given a single-use container of Refresh Plus ® artificial tears
           for self-application in case any ocular irritation is felt after impression cytology.

           The cells can then be processed after the patient's visit. Cells will be recovered from
           the EyePRIMTM filters using gentle agitation with a pipette tip for one minute, and then
           stained with antibody markers for dendritic cells (lymphoid and myeloid), NK cells, B
           cells, T cells , neutrophils and monocytes. Specifically, CD123, CD16, CD45, CD56, CD3,
           CD4, CD8, CD66b, CD11b, CD11c markers will be used.

           Cells harvested from impression cytology will be counted and undergo flow cytometry and
           depending on numbers, determination of the proportion of immune cells of various types,
           and even staining for Intracytoplasmic cytokines in lymphocytes after Phorbol Myristate
           Acetate stimulation. One modification of flow cytometry is the Amnis or microscopy
           coupled flow cytometry which can be performed at the SingHealth Immunology and
           Inflammation center. Amnis and microscopy couples flow cytometry can handle even less
           cells than conventional flow cytometry. If the cells from impression cytology are not
           sufficient for these purposes, nano-string transcript levels of various immune markers
           will be performed instead.

           3. Oculus K 5M imaging

      a. Non-Invasive Tear Break-Up Time (Oculus K5M) Non-Invasive Tear Break-Up Time is measured
      non-invasively and fully automatically using Oculus K5M. The new infrared illumination is not
      visible to the human eye. This prevents glare during the examination. Patient will sit
      comfortably in front of the instrument and blink freely while fixing on a target directly
      ahead. Once the participant is ready, they will be instructed to blink twice and refrain from
      blinking. Keratograph 5M is fully automated and it will capture any break or distortion in
      the image and the time of the break will be noted. Three readings will be taken for each eye
      to get the average value.

      b. Tear Meniscus Height (Oculus K5M) This can be measured non-invasively by the Oculus K5M to
      the nearest mm. Patient will sit comfortably in front of the instrument while fixing on a
      target directly ahead. Tear meniscus will be captured by the machine and tear meniscus height
      measured.

      c. Conjunctival redness (Oculus K5M) Conjunctival redness will be assessed using Oculus K5M.
      Patient will sit comfortably in front of the instrument while fixing on a target directly
      ahead. Imaged will be captured and an overview display of conjunctival redness will be
      evaluated by "JENVIS Grading Scale".

      4. Collection of blood via venipuncture (optional) 5-10ml of blood will be collected from
      patients via venipuncture. This is optional based on participant preference. Two different
      Participant Information Sheets have been prepared based on their choice of having
      venipuncture and disclosing its results. This will be taken on a non-study visit or when it
      is concurrent with a clinically indicated blood test.

      5. Retrieval of Clinical Information of participants

      Three areas of clinical information of the rheumatic status in our participants will be
      collected retrospectively. These areas are:

        1. Most recent serology results for autoantibody titres and other blood test results such
           as erythrocyte sedimentation rate

        2. History of drug prescriptions

        3. Disease activity index and other relevant clinical information

      We propose obtaining the data in 1) and 2) from the patient's electronic medical records via
      the Citrix XenApp portal. Disease activity index and other clinical information may be
      obtained from the case files of the patients.

      Rationale Small volumes of fluid can be used in a multiplex way to determine more than one
      cytokine in the Beadlyte assay, compared to ELISA.

      The EyePRIMTM technique is used because of prior studies that showed a high cellular yield
      and success in immune profiling with 3 healthy people.

      Expected findings:

        1. RA and SLE patients should have elevated tear cytokine levels and increased inflammatory
           cell population in their conjunctival samples.

        2. RA and SLE patients should have greater signs of ocular surface inflammation than the
           healthy controls

        3. The signs of ocular surface inflammation should correlate with disease activity, tear
           cytokines profiles and conjunctival inflammatory cell profiles.
observational model: Case-Control
time perspective: Cross-Sectional
measure: Profile tear cytokines
time frame: 1 day
description: the inflammatory cytokines concentration
measure: Profile immune response
time frame: 1 day
description: the levels of inflammatory gene transcripts, ie., pattern of immune gene expression.
Tear samples will be collected from the schimers strips for protein analysis
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 21 Years
maximum age: 99 Years
healthy volunteers: Accepts Healthy Volunteers
facility: 
country: Singapore
responsible party type: Principal Investigator
investigator affiliation: Singapore National Eye Centre
investigator full name: Louis Tong
investigator title: Clinician-Scientist, Senior Consultant
mesh term: Arthritis
mesh term: Arthritis, Rheumatoid
mesh term: Dry Eye Syndromes
mesh term: Lupus Erythematosus, Systemic